With a computer-generated randomisation sequence , we randomly allocated participants ( 2:1 ; blocks of six , stratified by efavirenz use at screening ) to switch to coformulated elvitegravir , cobicistat , emtricitabine , and tenofovir ( switch group ) or continue the NNRTI plus emtricitabine and tenofovir regimen ( no-switch group ) .